Literature DB >> 19733719

Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).

Yadong Cui1, Douglas J Watson, Cynthia J Girman, Deborah R Shapiro, Antonio M Gotto, Patricia Hiserote, Michael B Clearfield.   

Abstract

Reducing low-density lipoprotein (LDL) cholesterol with statins reduces cardiovascular risk, but the associations between increases in high-density lipoprotein (HDL) cholesterol and cardiovascular risk at different LDL levels have been less well characterized. To evaluate the associations between the 1-year changes in HDL cholesterol and LDL cholesterol with lovastatin and subsequent acute major coronary events (AMCEs), we studied 2,928 patients in the lovastatin arm who were followed for 5.2 years in a post-hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). The percentage of HDL cholesterol increase and apolipoproteins at year 1 and the incidence of AMCEs thereafter were assessed stratified by the LDL cholesterol levels. With lovastatin, LDL cholesterol was reduced by 25% on average to 115 mg/dl at year 1, and HDL cholesterol increased 6.0%. Patients with both an increase in HDL cholesterol of > or =7.5% and LDL cholesterol of <115 mg/dl at year 1 had the lowest event rate (3.53/1,000 person-years; p = 0.028). Similar results were found for an increase in HDL cholesterol of > or =7.5% and a decrease in LDL cholesterol of >25%, as well as for apolipoproteins A-I and B. The 1-year percent increase in HDL cholesterol appeared to be associated with a reduction in AMCEs in subsequent follow-up (p = 0.07 with the percentage of HDL cholesterol increase analyzed continuously). Patients with an HDL cholesterol increase of > or =7.5% had an AMCE rate of 5.18 compared with 7.66/1,000 person-years in patients with a lower HDL cholesterol increase (p = 0.08). In conclusion, lovastatin therapy was associated with a greater risk reduction of AMCEs when LDL cholesterol was substantially reduced and the HDL cholesterol increased by > or =7.5%.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19733719     DOI: 10.1016/j.amjcard.2009.05.020

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

Review 1.  The epidemiological concept of residual risk.

Authors:  Diego Vanuzzo
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

Review 2.  Pharmacomodulation of high-density lipoprotein metabolism as a therapeutic intervention for atherosclerotic disease.

Authors:  Peter P Toth
Journal:  Curr Cardiol Rep       Date:  2010-11       Impact factor: 2.931

3.  Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies.

Authors:  Parag H Joshi; Peter P Toth; Seth T Lirette; Michael E Griswold; Joseph M Massaro; Seth S Martin; Michael J Blaha; Krishnaji R Kulkarni; Arif A Khokhar; Adolfo Correa; Ralph B D'Agustino; Steven R Jones
Journal:  Eur J Prev Cardiol       Date:  2014-07-25       Impact factor: 7.804

Review 4.  Evacetrapib.

Authors:  Stephen J Nicholls
Journal:  Curr Cardiol Rep       Date:  2012-06       Impact factor: 2.931

Review 5.  Apo a-I modulating therapies.

Authors:  Stephen J Nicholls
Journal:  Curr Cardiol Rep       Date:  2011-12       Impact factor: 2.931

6.  Possible involvement of PPARγ-associated eNOS signaling activation in rosuvastatin-mediated prevention of nicotine-induced experimental vascular endothelial abnormalities.

Authors:  Sonam Kathuria; Nanjaian Mahadevan; Pitchai Balakumar
Journal:  Mol Cell Biochem       Date:  2012-11-10       Impact factor: 3.396

7.  In vitro and in vivo investigations on the effects of low-density lipoprotein concentration polarization and haemodynamics on atherosclerotic localization in rabbit and zebrafish.

Authors:  Xiang Xie; Ju Tan; Dangheng Wei; Daoxi Lei; Tieying Yin; Junli Huang; Xiaojuan Zhang; Juhui Qiu; Chaojun Tang; Guixue Wang
Journal:  J R Soc Interface       Date:  2013-02-28       Impact factor: 4.118

Review 8.  Statins for the primary prevention of cardiovascular disease.

Authors:  Fiona Taylor; Mark D Huffman; Ana Filipa Macedo; Theresa H M Moore; Margaret Burke; George Davey Smith; Kirsten Ward; Shah Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

9.  ST elevation acute myocardial infarction accelerates non-culprit coronary lesion atherosclerosis.

Authors:  Yunfeng Han; Jing Jing; Shengxian Tu; Feng Tian; Hao Xue; Weiren Chen; Jinsong Chen; Johan H C Reiber; Yundai Chen
Journal:  Int J Cardiovasc Imaging       Date:  2014-01-14       Impact factor: 2.357

Review 10.  Therapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studies.

Authors:  Jordan Andrews; Rishi Puri; Yu Kataoka; Stephen J Nicholls; Peter J Psaltis
Journal:  Cardiovasc Diagn Ther       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.